WASHINGTON - A drug made by Genentech received U.S. federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines.
Going against the recommendation of its advisory panel, the Food and Drug Administration cleared Genentech's Avastin, which is already approved for treating lung and colon cancer, based on findings that it slowed tumour growth.
The agency has traditionally approved drugs for late-stage cancer if they extended, or improved the quality of, patients' lives. Avastin showed neither, according to Genentech's application.
Wall Street analysts believe FDA's Avastin decision opens the door for other cancer drugs to be approved for their tumour-shrinking capabilities -- a trend that worries some health experts.
